简介:【摘要】:目的:研究乙肝病毒(HBV)携带产妇感染状态同胎儿宫内感染的相关性分析。方法:研究选取我院于2017年5月~2020年5月内疑似乙肝病毒携带产妇116例,其中,对其血清、乳汁及唾液采取乙肝表面抗原(HBsAg)、乙肝表面抗体(HBsAb)、乙肝e抗原(HBeAg)、乙肝e抗体(HBeAb)、乙肝核心抗体(HBcAb),待新生儿出生进行乙肝两对半检测,并部分孕妇实行HBN-DNA检测。结果:116例HBsAg阳性孕妇中,分娩的新生儿发生宫内感染为7.76%(9/116),经相关检验四种感染方式并未存在统计学意义(P>0.05)。四组组间乳汁阳性率差异存在统计学意义(即P
简介: 【摘要】目的 对乙肝病毒性肝炎进行分析,探究出对乙肝病毒性肝炎的预防控制措施。方法 选取 2018年 6月~ 2019年 6月在我院进行健康体检的健康人 96例作为研究对象,将其依据随机数字表法分为对照组和观察组,各 48例,对照组行常规预防措施,观察组在对照组的基础上行综合、全面性的防治控制措施,对两组预防控制措施的结果进行对比分析。结果 观察组总患病率为 4.17%明显低于对照组的 29.17%,观察组对疾病的总认知度为 95.83%明显高于对照组的 75.00%,两组比较,差异有统计学意义( P<0.05)。结论 综合、全面的乙肝病毒性肝炎防治控制措施可有效降低组员的感染率,提高组员对知识的了解,有较高的临床价值。 【关键词】乙肝病毒性肝炎;预防;控制;措施 [Abstract] Objective To analyze the hepatitis B and explore the preventive and control measures. Methods 96 healthy people who had physical examination in our hospital from June 2018 to June 2019 were selected as the research objects. They were divided into control group and observation group according to the random number table method, 48 cases in each group. The control group took routine preventive measures. The observation group took comprehensive and comprehensive preventive and control measures on the basis of the control group, and the results of the two groups were compared and analyzed. Results the total prevalence rate of the observation group was 4.17%, which was significantly lower than 29.17% of the control group. The total recognition of the observation group to the disease was 95.83%, which was significantly higher than 75.00% of the control group. The difference was statistically significant (P < 0.05). Conclusion comprehensive and comprehensive prevention and control measures of hepatitis B can effectively reduce the infection rate of the group members, improve the knowledge of the group members, and have high clinical value.
简介:【摘要】 目的 对比研究乙肝病毒感染血清标志物检测过程中应用两种不同免疫检验方法的临床价值。方法 选择在我院确定为乙肝病毒感染的患者 100例,根据治疗前所接受血清标志物免疫检验方法的不同,分成对照组( 50例)和研究组( 50例)。对照组治疗前采用酶联免疫吸附试验法进行血清标志物检测;研究组治疗前采用化学发光免疫分析法进行血清标志物检测。对比两组检测所需成本、检测所需时间、 HBsAg、 HBeAg、 HBeAb三种血清标志物检测的阳性率、对检测方案及结果的满意度。结果 研究组研究对象检测所需成本低于对照组;检测所需时间短于对照组; HBsAg、 HBeAg、 HBeAb三种血清标志物检测的阳性率水平高于对照组;对检测方案及结果的满意度达到 92.0%,高于对照组的 78.0%。组间数据差异有统计学意义( P< 0.05)。结论 乙肝病毒感染血清标志物检测过程中应用化学发光免疫分析法,可以缩短检查所需时间,降低检查成本,使检测结果的准确性和患者满意度得到同步提高。
简介:摘要:目的 : 本文主要针对 个性化 治疗 对终末期肾病血液透析患者依从性、满意度及生活质量的影响 进行分析研究 。方法 : 选择我院 2016 年 8 月— 2018 年 2 月收治的 104 例终末期肾病血液透析患者为研究对象,按照随机数字表法将其分为两组 : 研究组 (n=52) 、对照组 (n=52) 。对照组采用常规的内科 治疗 模式,在对照组 治疗 措施的基础上研究组患者实施个性化 治疗 模式。比较两组患者的治疗依从性、满意度以及 治疗 后的生活质量。结果 : 研究组患者的治疗依从性为 92 . 31% ,明显高于对照组的 78 . 85% ,差异有显著性 (P < 0 . 05) 。研究组患者的 治疗 满意度为 96 . 15% ,明显高于对照组的 80 . 77% ,差异有显著性 (P < 0 . 05) 。与对照组比较,研究组患者在躯体功能、心理功能、社会功能及物质功能评分方面均明显升高,差异有显著性 (P < 0 . 05) 。结论 : 个性化 治疗 可以显著提高终末期肾病血液透析患者的治疗依从性及 治疗 满意度,显著改善患者的生活质量。
简介:【摘要】目的 对终末期肾病患者血液透析治疗的同时采用左卡尼汀配合后的相关指标改善作用进行探析。方法 将我院在2018年1月至2020 年1月期间收治的终末期肾病患者纳入此次研究,纳入患者一共66例;按照电脑随机分配的方式分为常规组(n=33)和实验组(n=33),分别给予血液透析治疗和左卡尼汀配合治疗,对比两种治疗方案对患者相关指标的改善作用。结果 实验组的心功能指标和CT-GF以及NT-ProBNP水平相比常规组改善作用明显,经对比组间差异存在统计学意义(P<0.05)。结论 左卡尼汀配合血液透析治疗终末期肾病患者相关指标的改善作用明显,可进行临床推广和采纳。
简介:摘要:目的:对比研究腹膜透析治疗糖尿病肾病终末期患者的临床应用价值及血流动力学指标影响。方法:抽选本院糖尿病肾病患者共86例开展回顾性治疗研究,依据患者透析治疗方案分组,对照组(n=43,血液透析)、观察组(n=43,腹膜透析)。比较两组透析治疗后肾功能、血糖及血压量化指标变化及疗效差异。结果:两组治疗后血糖及血液量化指标组间对比结果无显著差异,P>0.05;治疗后,观察组SBP为(134.45±10.08)mmHg、DBP为(87.25±8.41)mmHg,较同期对照组差异显著,P0.05( =0.3454);观察组心血管不良预后发生率为2.33%(1/43),较对照组差异显著,P
简介:摘要:目的:分析病毒性肝病患者生化指标对其诊断的作用。方法:选取2019年至2020年到我院问诊并确诊为病毒性肝病的患者54人作为研究对象,将所有患者视为观察组,再选取54名身体健康的人员作为健康组。抽取所有患者的静脉血并使用全自动生化分析仪测定所有观察对象的各项生化指标,观察健康人群与病毒性肝病人群血清中各项生化指标的差异。结果:统计并记录所有人员的生化指标检测数据结果,发现观察组患者血清中TP含量、ALB含量、A/G比值均要明显低于健康组人员(P<0.05);根据最新生化指标检验标准显示,观察组患者血清内ALT含量、AST含量、ADA含量均要显著高于健康组人员(P<0.05)。结论:无论是以往的生化检验指标还是最新的生化检验指标,病毒性肝病患者血清中的生化指标数值与健康人群之间都存在较明显的差异,所以可以通过检测患者的血清对其进行病毒性肝病的诊断。
简介:摘要:重症肝病患者由于肝功能严重障碍 , 机体免疫功能低下 , 对感染应激能力下降 , 病程中易发生医院感染 , 而各种感染又进一步加重病情 , 直接影响患者的临床转归。综述了重症肝病患者医院感染的临床特点及危险因素。
简介:[摘要 ] 目的 比较化学发光免疫分析技术( CLIA)和酶联免疫吸附试验( ELISA)在乙肝病毒血清学检验中的应用价值。 方法 选取 2017年 1月~ 2019年 6月间我院收治的 80例疑似乙型肝炎患者,采用 CLIA法、 ELISA法对乙肝病毒血清学指标进行检测,以实时荧光定量 PCR检验结果作为参照,分析 CLIA法、 ELISA法對乙肝的诊断结果。 结果 ELISA法对乙肝的诊断灵敏度、特异度、准确性分别为 91.84%、 93.55%、 92.50%, CLIA法分别为 93.88%、 96.77%、 95.00%,二者比较均无统计学差异( P均 >0.05)。 CLIA法、 ELISA法对乙肝的诊断结果与实时荧光定量 PCR之间具有良好一致性, Kappa均 >0.7。 CLIA法对 HBsAg、 HBeAg、 HBeAb的阳性检出率高于 ELISA法( P<0.05),而在 HBsAb、 HBcAb阳性检出率比较无统计学差异( P>0.05)。 结论 CLIA法、 ELISA法对乙型肝炎的诊断效果均较好,而在乙肝病毒血清学标志物检验中, CLIA法的检验准确性高于 ELISA法。 [关键词 ] 乙型肝炎;乙肝病毒;血清学检验;化学发光免疫分析法;酶联免疫吸附试验 [Abstract] Objective To compare the application value of chemiluminescence immunoassay( CLIA) and enzyme-linked immunosorbent assay( ELISA) in serological testing of hepatitis B virus. Methods From January 2017 to June 2019, 80 patients with suspected hepatitis B who were admitted to our hospital were selected. CLIA method and ELISA method were used to determine the serological indices of hepatitis B virus. Real-time fluorescence quantitative PCR test results were used as the reference. The diagnosis results of hepatitis B by CLIA method and ELISA method were analyzed. Results The diagnostic sensitivity, specificity and accuracy of ELISA for hepatitis B were 91.84%, 93.55% and 92.50% respectively, and those of CLIA were 93.88%, 96.77%, 95.00% respectively. There was no statistically significant difference between the two methods( P>0.05 for all) . CLIA method and ELISA method for the diagnostic results of hepatitis B were well consistent with real-time fluorescence quantitative PCR( Kappa>0.7 for all) . The positive detection rate of HBsAg, HBeAg and HBeAb by CLIA was higher than that of ELISA( P<0.05), and the difference of positive detection rate of HBsAb and HBcAb was not statistically significant( P>0.05) . Conclusion CLIA method and ELISA method are favorable for the diagnosis of hepatitis B. In the hepatitis B virus serological marker test, the test accuracy of CLIA is higher than that of ELISA. [Key words] Hepatitis B; Hepatitis B virus; Serological testing; Chemiluminescence immunoassay( CLIA); Enzyme-linked immunosorbent assay( ELISA)
简介:【摘要】目的:对比分析在乙肝病毒血清学检验中,应用化学发光法与酶联免疫法的检验效果。方法:选取2019年1月-2020年09月间,在本院进行乙肝病毒血清学检验的66例疑似乙肝患者作为研究对象;为此次入院患者均实施乙肝病毒血清学检验,并采取化学发光法与酶联免疫法进行检验,对比两种检验方式的乙肝病毒标志物检出率。结果:经检测,化学发光法对多种乙肝病毒标志物——HBeAb、HBeAg、HBcAb、HBsAb、HBsAg的检出率分别为57.58%、40.91%、59.09%、62.12%、42.42%,相对比酶联免疫法的33.33%、22.73%、39.39%、43.94%、24.24%,均有明显提高(P
简介: [摘要 ] 目的 探讨风险管理在肝病患者护理中的应用效果。方法 选取 134例于 2018年 1月— 2020年 1月在该院接受治疗的肝病患者為研究对象,依护理方法不同分为对照组和研究组,于住院期间给予对照组常规护理,研究组风险管理护理,比较两组患者护理质量与护理风险事件发生情况。结果 研究组患者各项护理质量指标评分均明显高于对照组,组间比较差异有统计学意义( P<0.05) ;研究组患者护理风险事件的发生率为 1.49%,明显低于对照组的 13.43%,组间比较差异有统计学意义( P<0.05)。结论 针对肝病患者,于护理过程当中给予风险管理可有效提高护理质量,降低护理风险事件的发生率,取得良好护理效果,值得在临床当中推广应用。 [关键词 ] 肝病 ;护理 ;风险管理 [Abstract] Objective To explore the effect of risk management in the nursing of patients with liver disease. Methods 134 patients with liver disease who were treated in the hospital from January 2018 to January 2020 were selected as the research objects. According to different nursing methods, they were divided into control group and research group. During hospitalization, they were given routine nursing in the control group and risk management nursing in the research group. The quality of nursing and the occurrence of nursing risk events in the two groups were compared. Results the scores of nursing quality indexes in the study group were significantly higher than those in the control group, and the difference between the two groups was statistically significant (P < 0.05); the incidence of nursing risk events in the study group was 1.49%, significantly lower than 13.43% in the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion for patients with liver disease, risk management in the nursing process can effectively improve the quality of nursing, reduce the incidence of nursing risk events, and achieve good nursing effect, which is worthy of clinical application.
简介:[摘要 ] 目的 比较化学发光免疫分析技术( CLIA)和酶联免疫吸附试验( ELISA)在乙肝病毒血清学检验中的应用价值。 方法 选取 2017年 1月~ 2019年 6月间我院收治的 80例疑似乙型肝炎患者,采用 CLIA法、 ELISA法对乙肝病毒血清学指标进行检测,以实时荧光定量 PCR检验结果作为参照,分析 CLIA法、 ELISA法對乙肝的诊断结果。 结果 ELISA法对乙肝的诊断灵敏度、特异度、准确性分别为 91.84%、 93.55%、 92.50%, CLIA法分别为 93.88%、 96.77%、 95.00%,二者比较均无统计学差异( P均 >0.05)。 CLIA法、 ELISA法对乙肝的诊断结果与实时荧光定量 PCR之间具有良好一致性, Kappa均 >0.7。 CLIA法对 HBsAg、 HBeAg、 HBeAb的阳性检出率高于 ELISA法( P<0.05),而在 HBsAb、 HBcAb阳性检出率比较无统计学差异( P>0.05)。 结论 CLIA法、 ELISA法对乙型肝炎的诊断效果均较好,而在乙肝病毒血清学标志物检验中, CLIA法的检验准确性高于 ELISA法。 [关键词 ] 乙型肝炎;乙肝病毒;血清学检验;化学发光免疫分析法;酶联免疫吸附试验 [Abstract] Objective To compare the application value of chemiluminescence immunoassay( CLIA) and enzyme-linked immunosorbent assay( ELISA) in serological testing of hepatitis B virus. Methods From January 2017 to June 2019, 80 patients with suspected hepatitis B who were admitted to our hospital were selected. CLIA method and ELISA method were used to determine the serological indices of hepatitis B virus. Real-time fluorescence quantitative PCR test results were used as the reference. The diagnosis results of hepatitis B by CLIA method and ELISA method were analyzed. Results The diagnostic sensitivity, specificity and accuracy of ELISA for hepatitis B were 91.84%, 93.55% and 92.50% respectively, and those of CLIA were 93.88%, 96.77%, 95.00% respectively. There was no statistically significant difference between the two methods( P>0.05 for all) . CLIA method and ELISA method for the diagnostic results of hepatitis B were well consistent with real-time fluorescence quantitative PCR( Kappa>0.7 for all) . The positive detection rate of HBsAg, HBeAg and HBeAb by CLIA was higher than that of ELISA( P<0.05), and the difference of positive detection rate of HBsAb and HBcAb was not statistically significant( P>0.05) . Conclusion CLIA method and ELISA method are favorable for the diagnosis of hepatitis B. In the hepatitis B virus serological marker test, the test accuracy of CLIA is higher than that of ELISA. [Key words] Hepatitis B; Hepatitis B virus; Serological testing; Chemiluminescence immunoassay( CLIA); Enzyme-linked immunosorbent assay( ELISA)
简介:【摘要】目的:探讨腹膜透析联合血液透析治疗终末期肾病的临床效果。方法:选取我院诊断为终末期肾衰竭,接受肾脏替代治疗的患者,病因为肾小球肾炎、糖尿病肾病、高血压肾病、遗传性肾病。随机分为2组,研究组(接受腹膜透析与血液透析治疗)和对照组(接受腹膜透析治疗)。分析两组透析前后一般情况(体重、尿量、收缩压及舒张压);两组透析前后实验室指标改善情况。结果:两组透析前一般情况(体重、尿量、收缩压及舒张压)比较无差异(P>0.05);两组透析后一般情况(体重、尿量、收缩压及舒张压)比较有差异(P0.05);两组透析后实验室指标(血红蛋白、总蛋白、血白蛋白、总胆固醇、甘油三酯、血钙、血磷、PTH)比较有差异(P
简介: 摘要:目的:分析血清检验指标改变对甲亢性肝病患者的临床价值。方法:随机选择我院自 2018年 12月至 2019年 5月收治的 60例甲亢性肝病患者与同时期时段收治的甲亢患者 60例作为研究目标,将前者作为观察组、后者作为对照组。所有患者均应用血清检验,分析两组血清检验指标结果、肛功能五项指标。结果:血清检验指标结果、、肛功能五项指标对比显示观察组高于对照组( P<0.05)。结论:甲亢性肝病患者机体内的分泌水平明顯高于甲亢患者,其会影响患者正常的体能代谢,从而引发多种并发症。通过血清检验指标的改变,可提高甲亢性肝病的诊断效果,为临床诊治提供有利的参考依据,从而提高治疗效果,降低不可逆肝损伤发生几率,临床应用价值较高,值得推广。 关键词:血清检验指标;甲亢性肝病;应用价值 Abstract: Objective: to analyze the clinical value of the change of serum test index in patients with hyperthyroid liver disease. Methods: 60 patients with hyperthyroid liver disease admitted from December 2018 to may 2019 and 60 patients with hyperthyroid liver disease admitted in the same period were randomly selected as the research objectives, the former as the observation group and the latter as the control group. Serum test was used in all patients. The results of serum test and anal function were analyzed. Results: the results of serum test, anal function and five indexes of the observation group were higher than those of the control group (P < 0.05). Conclusion: the level of secretion in patients with hyperthyroid liver disease is significantly higher than that in patients with hyperthyroid liver disease, which will affect the normal physical metabolism of patients and lead to a variety of complications. Through the change of serum test index, the diagnosis effect of hyperthyroid liver disease can be improved, which can provide beneficial reference for clinical diagnosis and treatment, so as to improve the treatment effect, reduce the incidence of irreversible liver injury, and have high clinical application value, which is worth popularizing.